Biodesix (BDSX) revenue and earnings history
Biodesix reported revenue of $88.5M for fiscal 2025 (year ended Dec 31, 2025), +24.1% on the year before, and net income of −$35.3M.
Over 6 years, from fiscal 2019 to fiscal 2025, revenue grew at a compound rate of +23.8% a year.
Revenue and net income, 7 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $88.5M+24.1% | −$27.9M | −$35.3M | −$23.3M | $259K | −$23.5M | $4.14M | — | — | $19M | $50M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Biodesix (BDSX) on OQRO.
Common questions
What was Biodesix's revenue in fiscal 2025?
$88.5M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is +24.1% on fiscal 2024 ($71.3M).
How fast has Biodesix's revenue grown?
From $24.6M in fiscal 2019 to $88.5M in fiscal 2025: a compound annual growth rate of +23.8% over 6 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Biodesix been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Biodesix tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
